Cargando…

The prognostic relevance of urokinase-type plasminogen activator (uPA) in the blood of patients with metastatic breast cancer

In breast cancer (BC), elevated levels of urokinase-type plasminogen activator (uPA) in tumor tissue have been confirmed as a strong prognostic factor in level-of-evidence-1 studies. The aim of the present study was to evaluate the clinical relevance of uPA levels in serum of metastatic BC patients...

Descripción completa

Detalles Bibliográficos
Autores principales:	Banys-Paluchowski, Malgorzata, Witzel, Isabell, Aktas, Bahriye, Fasching, Peter A., Hartkopf, Andreas, Janni, Wolfgang, Kasimir-Bauer, Sabine, Pantel, Klaus, Schön, Gerhard, Rack, Brigitte, Riethdorf, Sabine, Solomayer, Erich-Franz, Fehm, Tanja, Müller, Volkmar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6381129/ https://www.ncbi.nlm.nih.gov/pubmed/30783124 http://dx.doi.org/10.1038/s41598-018-37259-2

Ejemplares similares

Evaluation of serum epidermal growth factor receptor (EGFR) in correlation to circulating tumor cells in patients with metastatic breast cancer
por: Banys-Paluchowski, Malgorzata, et al.
Publicado: (2017)

Elevated serum RAS p21 is an independent prognostic factor in metastatic breast cancer
por: Banys-Paluchowski, Malgorzata, et al.
Publicado: (2018)

Prognostic impact of circulating tumor cells assessed with the CellSearch System™ and AdnaTest Breast™ in metastatic breast cancer patients: the DETECT study
por: Müller, Volkmar, et al.
Publicado: (2012)

Prospective evaluation of serum tissue inhibitor of metalloproteinase 1 and carbonic anhydrase IX in correlation to circulating tumor cells in patients with metastatic breast cancer
por: Müller, Volkmar, et al.
Publicado: (2011)

The autoactivation of human single-chain urokinase-type plasminogen activator (uPA)
por: Torres-Paris, Constanza, et al.
Publicado: (2023)

Microglia and the urokinase plasminogen activator receptor/uPA system in innate brain inflammation
por: Cunningham, Orla, et al.
Publicado: (2009)

Comparison of the HER2, estrogen and progesterone receptor expression profile of primary tumor, metastases and circulating tumor cells in metastatic breast cancer patients
por: Aktas, Bahriye, et al.
Publicado: (2016)

Circulating and Disseminated Tumor Cells in Breast Carcinoma: Report from the Consensus Conference on Tumor Cell Dissemination during the 39th Annual Meeting of the German Society of Senology, Berlin, 27 June 2019
por: Banys-Paluchowski, Malgorzata, et al.
Publicado: (2019)

Multifunctional roles of urokinase plasminogen activator (uPA) in cancer stemness and chemoresistance of pancreatic cancer
por: Asuthkar, Swapna, et al.
Publicado: (2013)

Urokinase-type plasminogen activator (uPA) regulates invasion and matrix remodelling in colorectal cancer
por: Micalet, Auxtine, et al.
Publicado: (2023)

A Key Role for the Urokinase Plasminogen Activator (uPA) in Invasive Group A Streptococcal Infection
por: Sanderson-Smith, Martina L., et al.
Publicado: (2013)

Circulating and Disseminated Tumour Cells in Breast Carcinoma: Report from the Consensus Conference on Tumour Cell Dissemination during the 38th Annual Meeting of the German Society of Senology, Berlin, 14 June 2018
por: Banys-Paluchowski, Malgorzata, et al.
Publicado: (2019)

Inhibition of Human Urokinase-Type Plasminogen Activator (uPA) Enzyme Activity and Receptor Binding by DNA Aptamers as Potential Therapeutics through Binding to the Different Forms of uPA
por: Dreymann, Nico, et al.
Publicado: (2022)

Inhibition of urokinase plasminogen activator “uPA” activity alters ethanol consumption and conditioned place preference in mice
por: Al Maamari, Elyazia, et al.
Publicado: (2014)

Urokinase-type plasminogen activator (uPA) and its receptor (uPAR) promote neurorepair in the ischemic brain
por: Merino, Paola, et al.
Publicado: (2017)

Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas.
por: Bouchet, C., et al.
Publicado: (1994)

Urokinase plasminogen activator (uPA) and plasminogen activator inhibitor type-1 (PAI-1) in breast cancer - correlation with traditional prognostic factors
por: Lampelj, Maja, et al.
Publicado: (2015)

uPA-mediated plasminogen activation is enhanced by polyphosphate
por: Whyte, Claire S., et al.
Publicado: (2020)

Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications
por: Mahmood, Niaz, et al.
Publicado: (2018)

A Pilot Study of Urokinase-Type Plasminogen Activator (uPA) Overexpression in the Brush Cytology of Patients with Malignant Pancreatic or Biliary Strictures
por: Gibbs, John F., et al.
Publicado: (2009)

Urokinase-type Plasminogen Activator (uPA) is Inhibited with QLT0267 a Small Molecule Targeting Integrin-linked Kinase (ILK)
por: Santos, Nancy Dos, et al.
Publicado: (2007)

Detection and characterization of circulating tumor cells in blood of primary breast cancer patients by RT-PCR and comparison to status of bone marrow disseminated cells
por: Fehm, Tanja, et al.
Publicado: (2009)

Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program
por: Müller, V., et al.
Publicado: (2021)

Apoptosis-related deregulation of proteolytic activities and high serum levels of circulating nucleosomes and DNA in blood correlate with breast cancer progression
por: Roth, Carina, et al.
Publicado: (2011)

Combined mRNA expression levels of members of the urokinase plasminogen activator (uPA) system correlate with disease-associated survival of soft-tissue sarcoma patients
por: Kotzsch, Matthias, et al.
Publicado: (2011)

Correlation of Serum Levels of Urokinase Activation Plasminogen (uPA) and Its Inhibitor (PAI-1) with Hormonal and HER-2 Status in the Early Invasive Breast Cancer
por: Pusina, Sadat
Publicado: (2018)

Prognostic impact of urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) in cytosols and pellet extracts derived from 892 breast cancer patients
por: de Witte, J H, et al.
Publicado: (1999)

Systemic Therapy of Premenopausal Patients with Early Stage Hormone Receptor-Positive, HER2-Negative Breast Cancer – Controversies and Standards in Healthcare
por: Müller, Volkmar, et al.
Publicado: (2023)

Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients
por: Aktas, Bahriye, et al.
Publicado: (2009)

Update Breast Cancer 2022 Part 4 – Advanced-Stage Breast Cancer
por: Aktas, Bahriye, et al.
Publicado: (2022)

Update Breast Cancer 2022 Part 3 – Early-Stage Breast Cancer
por: Fehm, Tanja N., et al.
Publicado: (2022)

Update Breast Cancer 2022 Part 5 – Early Stage Breast Cancer
por: Fehm, Tanja N., et al.
Publicado: (2023)

Update Breast Cancer 2022 Part 6 – Advanced-Stage Breast Cancer
por: Lüftner, Diana, et al.
Publicado: (2023)

TEM8 functions as a receptor for uPA and mediates uPA-stimulated EGFR phosphorylation
por: Zhang, Lian-Cheng, et al.
Publicado: (2018)

Update Breast Cancer 2022 Part 2 – Advanced Stage Breast Cancer
por: Müller, Volkmar, et al.
Publicado: (2022)

Role of urokinase plasminogen activator and plasminogen activator inhibitor mRNA expression as prognostic factors in molecular subtypes of breast cancer
por: Witzel, Isabell, et al.
Publicado: (2014)

Explication of the roles of prostate health index (PHI) and urokinase plasminogen activator (uPA) as diagnostic and predictor tools for prostate cancer in equivocal PSA range of 4–10 ng/mL
por: Nassir, Anmar M., et al.
Publicado: (2020)

Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc
por: Kuhn, W, et al.
Publicado: (1999)

Gemcitabine treatment induces endoplasmic reticular (ER) stress and subsequently upregulates urokinase plasminogen activator (uPA) to block mitochondrial-dependent apoptosis in Panc-1 cancer stem-like cells (CSCs)
por: Wang, Li, et al.
Publicado: (2017)

Update Breast Cancer 2022 Part 1 – Early Stage Breast Cancer
por: Welslau, Manfred, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_57umfnptqi1c880p88ks2p5tuk